Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.

ABSTRACT:

Background

Posttherapy measurable residual disease (MRD) positivity in core binding factor acute myeloid leukemia (CBF-AML) is associated with shorter relapse-free survival (RFS). Elimination of MRD measured via quantitative reverse transcription polymerase chain reaction (qRTPCR) for disease specific transcripts can potentially lead to better outcomes in CBF-AML.

Methods

We prospectively monitored the MRD using qRTPCR and flow cytometry on bone marrow samples in patients with newly diagnosed CBF-AML who received decitabine (DAC) maintenance therapy after fludarabine/cytarabine/G-CSF (FLAG)-based induction/consolidation regimen. Negative qRTPCR (CMR) was defined as fusion transcript <0.01%.

Results

Thirty-one patients with CBF-AML including 14 with t(8;21) and 17 with

SUBMITTER: Senapati J 

PROVIDER: S-EPMC9303262 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature